Peter R. Galle, MD, PhD, Mainz University Medical Center

Articles by Peter R. Galle, MD, PhD, Mainz University Medical Center

HCC Global Screening Programs for At-Risk Populations

ByPeter R. Galle, MD, PhD, Mainz University Medical Center,Minsig Choi, MD, Stony Brook University Hospital,Masatoshi Kudo, MD, PhD, Kindai University Faculty of Medicine,Kate Kelley, MD, UCSF Health

June 29th 2020

HCC Etiologic Risk Factors and Global Prevalence

ByPeter R. Galle, MD, PhD, Mainz University Medical Center,Minsig Choi, MD, Stony Brook University Hospital,Masatoshi Kudo, MD, PhD, Kindai University Faculty of Medicine,Kate Kelley, MD, UCSF Health

June 29th 2020

Dr. Galle on Patient-Reported Outcomes From the Phase III IMbrave150 Trial

ByPeter R. Galle, MD, PhD, Mainz University Medical Center

January 26th 2020

Peter R. Galle, MD, discusses the patient-reported outcomes results from the Phase III IMbrave150 study, which he presented at the 2020 Gastrointestinal Cancers Symposium

Peter R. Galle, MD, PhD, Mainz University Medical Center

Articles by Peter R. Galle, MD, PhD, Mainz University Medical Center

HCC Global Screening Programs for At-Risk Populations

HCC Etiologic Risk Factors and Global Prevalence

Dr. Galle on Patient-Reported Outcomes From the Phase III IMbrave150 Trial

Trending on OncLive

INBRX-106 Plus Pembrolizumab Improves Responses and PFS in First-Line PD-L1–Positive HNSCC

FDA Approves Pirtobrutinib for Previously Untreated CLL/SLL

AUA Releases Guideline Amendment for NMIBC

Five Under 5: Top Oncology Videos for the Week of 9/27

‘Our Impact Will Be Broad and Transformative’: Wells Messersmith, MD, Takes the Reins at CU Anschutz Cancer Center